Mia's Feed
Medical News & Research

Study Highlights Use of Long-Acting Contraceptives in 26 African Countries

Study Highlights Use of Long-Acting Contraceptives in 26 African Countries

Share this article

A comprehensive study across 26 African countries reveals the usage patterns of long-acting reversible contraceptives and highlights opportunities to improve family planning access in the region.

2 min read

A recent study exploring reproductive health practices across 26 sub-Saharan African nations has shed light on the utilization of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants. These methods, which include hormonal and copper-based options, offer several advantages, notably their high effectiveness and duration of protection ranging from three to ten years. Once inserted by trained healthcare providers, they work continuously without requiring daily attention, with failure rates of less than 1%, significantly lower than short-term methods like pills or condoms.

LARCs are reversible; fertility typically resumes quickly after removal, making them a flexible choice for women who may wish to conceive in the future. Their adoption has increased in high-income countries due to policies promoting access, awareness campaigns, and integration into routine health services. However, in many parts of Africa, their overall use remains limited. The study found that on average, 21.7% of sexually active women in these countries use LARCs, indicating a heavy reliance on short-term contraceptive methods.

Among the studied nations, Benin, Mali, and Tanzania demonstrated higher usage rates, with nearly half or more women opting for long-acting options. Conversely, Namibia, Togo, and Niger showed minimal use, with prevalence rates below 5%. This disparity reflects differences in healthcare infrastructure, cultural norms, government policies, and community education.

Barriers to wider use include limited access to trained providers, stock shortages, higher out-of-pocket costs, and prevalent myths about infertility and health risks associated with these contraceptives. Addressing these challenges requires multi-faceted strategies: improving supply chains, training healthcare workers, conducting culturally sensitive education campaigns, and enhancing affordability.

Efforts to expand the availability of LARCs are essential for reducing unintended pregnancies and improving maternal health outcomes across the continent. By learning from the success stories of countries with higher adoption rates, African nations can implement targeted interventions, promote informed choices, and leverage community engagement to overcome misconceptions. Ultimately, increasing access to and awareness of long-acting contraceptives can play a vital role in empowering women and supporting reproductive rights.

Source: https://medicalxpress.com/news/2025-09-birth-africa-tracks-contraception-countries.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Why New Zealand’s Limited Access to the Cochrane Library Raises Concerns

New Zealand is reducing access to the Cochrane Library, a vital source of independent health evidence, raising concerns about health equity and informed decision-making. Learn about the implications of this policy change.

States Take Independent Action to Rebuild Public Trust Amid Confusion Over US Vaccine Policies

More states are taking independent steps to restore public trust and coordinate vaccine efforts amidst confusion over federal recommendations, highlighting regional leadership in public health.

RFK Jr. Calls Off Critical US Health Panel Meeting Without Notice, Sparking Concerns

U.S. Health Secretary Kennedy unexpectedly canceled a key preventive health advisory panel meeting, raising concerns over political influence and the future of science-based health policy in the United States.

Patients Choosing Extended 10-Year Hormone Therapy for Breast Cancer

A recent study reveals that nearly half of women with early-stage breast cancer are opting for extended 10-year hormone therapy to reduce recurrence risk, especially among higher-risk groups. The decision is influenced by doctor recommendations and personal concerns about cancer recurrence, highlighting the importance of shared decision-making in personalized cancer treatment.